Xeltis News
The patient-centric approach of Xeltis restorative devices at LSX World Congress
Laura Monti2022-05-11T12:10:37+01:00May 11th, 2022|Latest News|
CEO Eliane Schutte shared how Xeltis restorative devices can help combine clinical needs with a patient-centric approach in cardiovascular treatment. Speaking today at LSX World Congress 2022 in London, Eliane explained how the most advanced [...]
Promising early puncturing, patency and safety data for aXess in patients
Laura Monti2022-04-26T21:45:25+01:00April 27th, 2022|Latest News|
Preliminary results from a clinical trial of Xeltis’ restorative hemodialysis access graft, aXess, showed very promising early puncturing, functional patency and safety data. The data, from the ongoing first-in-human aXess trial, will be presented [...]
aXess and new directions for vascular access grafts
Laura Monti2022-04-08T16:50:57+01:00April 8th, 2022|Latest News|
Renal Interventions dedicated a feature article to arteriovenous grafts (AVG) for hemodialysis access, in which Xeltis’ restorative AVG graft aXess is prominently discussed among promising novel devices in vascular access. According to RI, aXess [...]
Xeltis pioneers supramolecular materials for cardiovascular restoration in patients
Laura Monti2022-04-05T17:12:36+01:00April 5th, 2022|Latest News|
Xeltis’ devices are the first living applications of supramolecular materials for cardiovascular restoration in patients. An article published in peer-reviewed journal Materials Today showcases how Xeltis implanted the first clinical devices made of supramolecular biomaterials [...]
XABG preclinical trial showed superior performance vs harvested veins at one year
Laura Monti2022-03-11T15:29:33+01:00March 11th, 2022|Latest News|
Results from preclinical trials of Xeltis restorative coronary artery bypass graft XABG showed superior performance of the Xeltis graft compared to harvested saphenous veins at one year. The data have been presented at the [...]
aXess trial proceeding at full speed following successful EU financing
Laura Monti2022-03-11T15:30:44+01:00March 10th, 2022|Latest News|
The aXess clinical study of Xeltis restorative access graft for hemodialysis is proceeding at full speed, announced today Xeltis CEO Eliane Schutte at Biocapital Europe. Over 350 successful dialysis sessions have been completed in [...]
Vascular experts discuss aXess in dialysis patients
Laura Monti2022-01-12T13:34:19+01:00January 12th, 2022|Latest News|
Matteo Tozzi, MD, vascular surgeon and professor of vascular surgery at Università dell’Insubria in Italy, and Frans L. Moll, MD, PhD, professor emeritus of vascular surgery at the University Medical Center Utrecht in The Netherlands, provided insights on the progress of [...]
Xeltis receives €15M funding from EIC Accelerator
Laura Monti2021-12-20T23:28:32+01:00December 21st, 2021|Latest News|
Xeltis will receive €15 million in funding from the European Innovation Council Accelerator (EIC) set up by the European Commission. The EIC funding comprises €2.5 millions in grants and up to €12.5 millions in [...]
First restorative hemodialysis access graft implanted in patients
Laura Monti2021-12-19T23:17:12+01:00December 20th, 2021|Latest News|
Xeltis has initiated the clinical trial for aXess, the first-ever restorative synthetic haemodialysis access graft. Several patients with kidney failure or advanced kidney disease requiring dialysis have already been successfully implanted as part of [...]
Xeltis hires VP for Heart Valves
Laura Monti2021-12-13T12:41:35+01:00December 13th, 2021|Latest News|
The Xeltis Executive Team has been joined by seasoned medtech business leader David Mester as Vice-President, Business Lead, Valve. David has over 30 years of experience in structural heart devices and dedicated his career [...]